GlassScriptPhysician profile
Travis Andrew Kyle
NPI 1003584608
$1,480.32
in general payments reported to CMS, 2019-2025
28 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $176 · 2023: $271 · 2024: $602 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,304.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,303.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $240.98 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $237.37 | 2022-2025 | |
| Astellas Pharma US INC | $149.53 | 2022-2025 | Veozah |
| Lilly USA, LLC | $145.56 | 2022-2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $89.33 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $63.17 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $51.15 | 2024-2025 | Gemtesa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.68 | 2025 | Caplyta |
| Glaxosmithkline, LLC. | $34.91 | 2025 | Arexvy, Shingrix |
| Dexcom, INC. | $34.69 | 2024-2025 | Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $34.32 | 2024 | Airsupra |
| Pfizer INC. | $33.87 | 2025 | |
| Antares Pharma, INC. | $30.09 | 2024-2025 | Xyosted |
| Merck Sharp & Dohme LLC | $29.06 | 2024-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Bioventus LLC | $28.46 | 2023 | Durolane |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $25.12 | 2024 | Rexulti |
| Phadia US INC. | $24.93 | 2024 | Immunocap |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.92 | 2024 | Trulance, Xifaxan |
| Mannkind Corporation | $19.94 | 2022 | |
| Nevro Corp. | $19.87 | 2024 | Senza |
| Otsuka America Pharmaceutical, INC. | $18.84 | 2023 | Rexulti |
| Boston Scientific Corporation | $17.81 | 2025 | Accolade Sr |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.49 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.27 | 2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $16.18 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.63 | 2023 | Lifevest |
| Sanofi-Aventis U.S. LLC | $15.16 | 2022 | |
| Currax Pharmaceuticals LLC | $12.99 | 2023 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Travis Kyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.